Drugs / INO-5151
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03835533 | Jun 2019 → Oct 2022 | prostate carcinoma | Parker Institute for Cancer Immunotherapy | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-07-29 | Inovio Pharmaceuticals | Inovio’s Cancer Immunotherapy (INO-5151) Targeting Prostate Cancer in Innovative Cancer Combination Trial inovio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INO-5151 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03835533 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT03835533 ↗ |